Login to Your Account

VBL brain cancer results in phase II encouraging; gene therapy advances

By Randy Osborne
Staff Writer

Wednesday, March 25, 2015

For VBL Therapeutics Inc., positive interim top-line phase II data with its gene therapy for recurrent glioblastoma took the sting out of February's news with a separate compound targeting psoriasis and ulcerative colitis, also each in a phase II trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription